DOCSLIB.ORG

Patient-Assistance-Reimbursement-Guide-2019.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patient-Assistance-Reimbursement-Guide-2019.Pdf ASSOCIATION OF COMMUNITY CANCER CENTERS Patient & Reimbursement Guide 2019 PATIENT ASSISTANCE AND REIMBURSEMENT GUIDE 1 ASSOCIATION OF COMMUNITY CANCER CENTERS Patient & Reimbursement 3 Financial Toxicity Navigation Process Improvement Guide by Natasha Gomes 8 Patient Assistance Program Flowchart Pharmaceutical Company Patient Medical Device & Testing Patient Assistance & Reimbursement Programs Assistance & Reimbursement Programs AbbVie, Inc. 13 Adaptive Biotechnologies 76 Amgen, Inc. 14 Foundation Medicine 77 Array BioPharma 16 Astellas Pharma US, Inc. 17 Other Patient Assistance Programs & Resources AstraZeneca 19 Agingcare.com® 80 Bayer HealthCare Pharmaceuticals, Inc. 21 BenefitsCheckUp® 80 Boehringer Ingelheim Pharmaceuticals, Inc. 24 CancerCare® 80 Bristol-Myers Squibb 26 CancerCare® Co-payment Assistance Foundation 81 Celgene Oncology 28 Cancer Financial Assistance Coalition 81 Coherus BioSciences 30 Co-Pay Relief 82 Eisai Co., Ltd. 32 FamilyWize® 82 Eli Lilly and Company 34 Good Days® 82 EMD Serono, Inc. and Pfizer, Inc. 37 HealthWell Foundation® 83 Exelixis, Inc. 39 The Leukemia & Lymphoma Society 84 Genentech, Inc. 41 NeedyMeds 84 Heron Therapeutics 43 Partnership for Prescription Assistance 85 Incyte Corporation 45 Patient Access Network Foundation 86 Ipsen Biopharmaceuticals, Inc. 47 Patient Advocate Foundation 86 Janssen Biotech, Inc. 49 RxAssist 87 Kite Pharma 52 RxHope™ 87 Merck 53 Rx Outreach® 87 Mylan 55 Novartis Pharmaceuticals Corporation 57 Pfizer, Inc. 59 Pharmacyclics, LLC 61 Puma Biotechnology 62 Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme 64 Sandoz, Inc. 66 Seattle Genetics 67 The ACCC Patient Assistance & Reimbursement Guide was Taiho Oncology 68 printed in January 2019. This publication is updated four times Takeda Oncology 69 a year. Visit accc-cancer.org/PatientAssistanceGuide to TerSera Therapeutics 72 download and print the most up-to-date information on cancer drug assistance and reimbursement programs. Tesaro, Inc. 73 Teva Oncology 75 2019 PATIENT ASSISTANCE AND REIMBURSEMENT GUIDE 1 Patient Assistance and Reimbursement Assistance Programs by Drug or Product Abraxane® (paclitaxel protein-bound particles Faslodex® (fulvestrant) 19 for injectable suspension) (albumin-bound) 28 Femara® (letrozole) tablets 57 Actiq® (oral transmucosal fentanyl citrate) [C-II] 75 Fentora® (fentanyl buccal tablet) [C-II] 75 Adcetris® (brentuximab vedotin) for injection 67 Fulphila® (pegfilgrastim-jmdb) injection 55 Afinitor® (everolimus) tablets 57 Gardasil®9 (Human Papillomavirus 9-valent Afinitor Disperz® (everolimus) tablets for Vaccine, Recombinant) 53 oral suspension 57 Gazyva® (obinutuzumab) 41 Alecensa® (alectinib) capsules 41 Gilotrif® (afatinib) 24 Alimta® (pemetrexed for injection) 34 Gleevec® (imatinib mesylate) tablets 57 Aliqopa™ (copanslib) for injection 21 Granix® (tbo-filgrastim) for injection 75 Aloxi® (palonosetron hydrochloride) injection 32 Halaven® (eribulin mesylate) 32 Alunbrig® (brigatinib) tablets 69 Herceptin® (trastuzumab) 41 Aranesp® (darbepoetin alfa) 14 Herceptin Hylecta™ (trastuzumab and Aromasin® (exemestane) tablets 59 hyaluronidase-oysk) 41 Arzerra® (ofatumumab) injection 57 Ibrance® (palbociclib) 59 Avastin® (bevacizumab) 41 Iclusig® (ponatinib) 69 Balversa™ (erdafitinib) 49 Idamycin PFS® (idarubicin hydrochloride) Bavencio® (avelumab) injection 37, 59 for injection 59 Bendeka® (bendamustine hydrochloride) Idhifa® (enasidenib) 28 for injection 75 Imbruvica® (ibrutinib) 61 Besponsa® (inotuzumab ozogamicin) for injection 59 Imfinzi® (durvalumab) injection 19 Blincyto® (blinatumomab) 14 Imlygic® (talimogene laherparepvec) suspension Bosulif® (bosutinib) tablets 59 for intralesional injection 14 Braftovi® (encorafenib) capsules 16 Inlyta® (axitinib) tablets 59 Cabometyx® (cabozantinib) tablets 39 Intron® A (interferon alfa-2b, recombinant) Calquence® (acalabrutinib) 19 for injection 53 Camptosar® (irinotecan hydrochloride injection) 59 Iressa® (gefitinib) 19 Cinvanti® (aprepitant) injectable emulsion 43 Jadenu® (deferasirox) tablets 57 Cometriq® (cabozantinib) capsules 39 Jakafi® (ruxolitinib) tablets 45 Cotellic® (cobimetinib) tablets 41 Kadcyla® (ado-trastuzumab emtansine) 41 Cyramza® (ramucirumab) 34 Kanjinti™ (trastuzumab-anns) 14 Darzalex® (daratumumab) 49 Keytruda® (pembrolizumab) 53 Daurismo™ (glasdegib) 59 Kisqali® (ribociclib) tablets 57 Doxil® (doxorubicin HCl liposome injection) 49 Kymriah® (tisagenlecleucel) suspension Ellence® (epirubicin hydrochloride injection) 59 for IV infusion 57 Emcyt® (estramustine phosphate sodium Kyprolis® (carfilzomib) for injection 14 capsules) 59 Lartruvo® (olaratumab) 34 Emend® (aprepitant) 53 Lenvima® (lenvatinib) capsules 32 Emend® (fosaprepitant) for injection 53 Libtayo® (cemiplimab-rwlc) 64 Empliciti® (elotuzumab) 26 Lonsurf® (trifluridine and tipiracil) tablets 68 Erbitux® (cetuximab) 34 Lorbrena® (lorlatinib) 59 Erleada® (apalutamide) 49 Lumoxiti™ (moxetumomab pasudotox-tdfk) 19 Erivedge® (vismodegib) 41 Lupron Depot® (leuprolide acetate for depot Exjade® (deferasirox) tablets 57 suspension) 13 Farydak® (panobinostat) capsules 57 Lynparza® (olaparib) tablets and capsules 19 2019 PATIENT ASSISTANCE AND REIMBURSEMENT GUIDE 1 Patient Assistance and Reimbursement Assistance Programs by Drug or Product (continued) Mektovi® (binimetinib) tablets 16 Tarceva® (erlotinib) 17, 41 Mekinist® (trametinib) tablets 57 Tasigna® (nilotinib) tablets 57 Mylotarg™ (gemtuzumab ozogamicin) Tecentriq® (atezolizumab) for injection 41 for injection 59 Temodar® (temozolomide) 53 Nerlynx® (neratinib) 62 Thalomid® (thalidomide) 28 Neulasta® (pegfilgrastim) 14 Torisel® (temsirolimus) for injection 59 Neulasta® Onpro® (pegfilgrastim) injection kit 14 Trazimera™ (trastuzumab-qyyp) 59 Improving patient flow Neupogen® (filgrastim) 14 Treanda® (bendamustine HCl) for injection 75 by optimizing EHRs Nexavar® (sorafenib) tablets 21 Trisenox® (arsenic trioxide) for injection 75 Ninlaro® (ixazomib) capsules 69 Tykerb® (lapatinib) tablets 57 Nplate® (romiplostim) 14 Udenyca® (pegfilgrastim-cbqv) 30 Odomzo® (sonidegib) 57 Varubi® (rolapitant) tablets 72 Onivyde® (irinotecan liposome injection) 47 Vectibix® (panitumumab) 14 Opdivo® (nivolumab) 26 Velcade® (bortezomib) for injection 69 Perjeta® (pertuzumab) for injection 41 Venclexta® (venetoclax) 41 Piqray® (alpelisib) 57 Verzenio® (abemaciclib) 34 Polivy™ (polatuzumab vedotin-piiq) 41 Vidaza® (azacitidine) 28 Pomalyst® (pomalidomide) 28 Vitrakvi® (larotrectinib) 59 Portrazza® (necitumumab) 34 Vizimpro® (dacomitinib) 59 Procrit® (epoetin alfa) 49 Votrient® (pazopanib) tablets 57 Prolia® (denosumab) 14 Xalkori® (crizotinib) capsules 59 Promacta® (eltrombopag) tablets 57 Xgeva® (denosumab) 14 Revlimid® (lenalidomide) 28 Xofigo® (radium Ra 223 dichloride) injection 21 Rituxan® (rituximab) 41 Xospata® (gilteritinib) tablets 17 Rituxan Hycela® (rituximab/hyaluronidase human) Xtandi® (enzalutamide) capsules 17 for injection 41 Yervoy® (ipilimumab) 26 Rydapt® (midostaurin) 57 Yescarta® (axicabtagene ciloleucel) suspension Sandostatin® (octreotide acetate) for injection 57 for infusion 52 Sandostatin® LAR Depot (octreotide acetate Yondelis® (trabectedin) 49 for injectable suspension) 57 Zarxio® (filgrastim-sndz) 66 Sensipar® (cinacalcet) 14 Zejula® (niraparib) 73 Somatuline® Depot (lanreotide) for injection 47 Zelboraf® (vemurafenib) 41 Sprycel® (dasatinib) 26 Zinecard® (dexrazoxane) for injection 59 Stivarga® (regorafenib) tablets 21 Zirabev™ (bevacizumab-bvzr) 59 Sustol® (granisetron) extended-release injection 43 Zoladex® (goserelin acetate implant) 72 Sutent® (sunitinib malate) 59 Zolinza® (vorinostat) 53 Sylatron® (peginterferon alfa-2b) for injection 53 Zykadia® (ceritinib) capsules 57 Sylvant® (siltuximab) 49 Zytiga® (abiraterone acetate) 49 Synribo® (omacetaxine mepesuccinate) for injection 75 Tafinlar® (dabrafenib) capsules 57 Tagrisso® (osimertinib) 19 Talzenna® (talazoparib) 59 2 ASSOCIATION OF COMMUNITY CANCER CENTERS 2019 PATIENT ASSISTANCE AND REIMBURSEMENT GUIDE 3 Financial Toxicity NavigationBY NATASHA GOMES Process Improvement FINANCIAL TOXICITY NavigationImproving patient Process flow by Improvement optimizing EHRs Improving patient flow by optimizing EHRs inances are often a major concern for patients electronic health record (EHR) has allowed us to manage dealing with a cancer diagnosis. In 2017 DuPage this heavy caseload. Medical Group, Downers Grove, Ill., directed more attention and resources toward our financial Leveraging our Epic EHR to better support financial Fnavigation department to assist patients in minimizing navigation of patients along the care continuum, DuPage out-of-pocket expenses. Adding financial navigators Medical Group is able to: to the conversation and communication process helps • Capture patients from the time an order for bridge the gap for a patient deciding whether to start treatment is placed or continue treatment, as financial navigators provide • Develop communications with oncology and patients with exceptional, personalized care and guid- infusion patients ance throughout the course of their treatment. This also • Follow up on patient accounts eases the burden on our clinical staff by allowing them to • Track billing to co-pay assistance programs and focus on their areas of expertise. foundations. DuPage Medical Group is the largest physician-owned Since implementing this process in June 2017, DuPage group in Illinois, with more than 700 physicians, 115 Medical Group has tripled patient enrollment in co-pay locations, and 6 infusion sites that average 700 scheduled and
Load more

Recommended publications
  • An Overview of the Role of Hdacs in Cancer Immunotherapy
    International Journal of Molecular Sciences Review Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy Debarati Banik, Sara Moufarrij and Alejandro Villagra * Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, 800 22nd St NW, Suite 8880, Washington, DC 20052, USA; [email protected] (D.B.); [email protected] (S.M.) * Correspondence: [email protected]; Tel.: +(202)-994-9547 Received: 22 March 2019; Accepted: 28 April 2019; Published: 7 May 2019 Abstract: Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors (HDACis) have positioned these agents as promising drug candidates in combatting cancer, autoimmune, neurodegenerative, and infectious diseases. The same has also encouraged the evaluation of multiple HDACi candidates in preclinical studies in cancer and other diseases as well as the FDA-approval towards clinical use for specific agents. In this review, we have discussed how the efficacy of immunotherapy can be leveraged by combining it with HDACis. We have also included a brief overview of the classification of HDACis as well as their various roles in physiological and pathophysiological scenarios to target key cellular processes promoting the initiation, establishment, and progression of cancer. Given the critical role of the tumor microenvironment (TME) towards the outcome of anticancer therapies, we have also discussed the effect of HDACis on different components of the TME. We then have gradually progressed into examples of specific pan-HDACis, class I HDACi, and selective HDACis that either have been incorporated into clinical trials or show promising preclinical effects for future consideration.
    [Show full text]
  • North American Brain Tumor Consortium Study 04-03
    Published OnlineFirst August 24, 2012; DOI: 10.1158/1078-0432.CCR-12-1841 Clinical Cancer Cancer Therapy: Clinical Research Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03 Eudocia Q. Lee1, Vinay K. Puduvalli2, Joel M. Reid3, John G. Kuhn4, Kathleen R. Lamborn5, Timothy F. Cloughesy6, Susan M. Chang5, Jan Drappatz1,7, W. K. Alfred Yung2, Mark R. Gilbert2, H. Ian Robins8, Frank S. Lieberman7, Andrew B. Lassman9, Renee M. McGovern3, Jihong Xu2, Serena Desideri10, Xiabu Ye10, Matthew M. Ames3, Igor Espinoza-Delgado11, Michael D. Prados5, and Patrick Y. Wen1 Abstract Purpose: A phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG). Experimental Design: This phase I, dose-finding, investigational study was conducted in two parts. Part 1 was a dose-escalation study of vorinostat in combination with TMZ 150 mg/m2/day for 5 days every 28 days. Part 2 was a dose-escalation study of vorinostat in combination with TMZ 150 mg/m2/day for 5 days of the first cycle and 200 mg/m2/day for 5 days of the subsequent 28-day cycles. Results: In part 1, the MTD of vorinostat administered on days 1 to 7 and 15 to 21 of every 28-day cycle, in combination with TMZ, was 500 mg daily. Dose-limiting toxicities (DLT) included grade 3 anorexia, grade 3 ALT, and grade 5 hemorrhage in the setting of grade 4 thrombocytopenia.
    [Show full text]
  • Standard Oncology Criteria C16154-A
    Prior Authorization Criteria Standard Oncology Criteria Policy Number: C16154-A CRITERIA EFFECTIVE DATES: ORIGINAL EFFECTIVE DATE LAST REVIEWED DATE NEXT REVIEW DATE DUE BEFORE 03/2016 12/2/2020 1/26/2022 HCPCS CODING TYPE OF CRITERIA LAST P&T APPROVAL/VERSION N/A RxPA Q1 2021 20210127C16154-A PRODUCTS AFFECTED: See dosage forms DRUG CLASS: Antineoplastic ROUTE OF ADMINISTRATION: Variable per drug PLACE OF SERVICE: Retail Pharmacy, Specialty Pharmacy, Buy and Bill- please refer to specialty pharmacy list by drug AVAILABLE DOSAGE FORMS: Abraxane (paclitaxel protein-bound) Cabometyx (cabozantinib) Erwinaze (asparaginase) Actimmune (interferon gamma-1b) Calquence (acalbrutinib) Erwinia (chrysantemi) Adriamycin (doxorubicin) Campath (alemtuzumab) Ethyol (amifostine) Adrucil (fluorouracil) Camptosar (irinotecan) Etopophos (etoposide phosphate) Afinitor (everolimus) Caprelsa (vandetanib) Evomela (melphalan) Alecensa (alectinib) Casodex (bicalutamide) Fareston (toremifene) Alimta (pemetrexed disodium) Cerubidine (danorubicin) Farydak (panbinostat) Aliqopa (copanlisib) Clolar (clofarabine) Faslodex (fulvestrant) Alkeran (melphalan) Cometriq (cabozantinib) Femara (letrozole) Alunbrig (brigatinib) Copiktra (duvelisib) Firmagon (degarelix) Arimidex (anastrozole) Cosmegen (dactinomycin) Floxuridine Aromasin (exemestane) Cotellic (cobimetinib) Fludara (fludarbine) Arranon (nelarabine) Cyramza (ramucirumab) Folotyn (pralatrexate) Arzerra (ofatumumab) Cytosar-U (cytarabine) Fusilev (levoleucovorin) Asparlas (calaspargase pegol-mknl Cytoxan (cyclophosphamide)
    [Show full text]
  • Broad-Spectrum HDAC Inhibitors Promote Autophagy Through FOXO Transcription Factors in Neuroblastoma
    cells Article Broad-Spectrum HDAC Inhibitors Promote Autophagy through FOXO Transcription Factors in Neuroblastoma Katharina Körholz 1,2, Johannes Ridinger 1,2, Damir Krunic 3, Sara Najafi 1,2,4, Xenia F. Gerloff 1,2,4, Karen Frese 5, Benjamin Meder 5,6, Heike Peterziel 1,2, Silvia Vega-Rubin-de-Celis 7, Olaf Witt 1,2,4 and Ina Oehme 1,2,* 1 Hopp Children’s Cancer Center Heidelberg (KiTZ), 69120 Heidelberg, Germany; [email protected] (K.K.); [email protected] (J.R.); s.najafi@kitz-heidelberg.de (S.N.); [email protected] (X.F.G.); [email protected] (H.P.); [email protected] (O.W.) 2 Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), German Cancer Research Consortium (DKTK), INF 280, 69120 Heidelberg, Germany 3 Light Microscopy Facility (LMF), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; [email protected] 4 Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, 69120 Heidelberg, Germany 5 Institute for Cardiomyopathies Heidelberg, Heidelberg University, 69120 Heidelberg, Germany; [email protected] (K.F.); [email protected] (B.M.) 6 Genome Technology Center, Stanford University, Stanford, CA 94304, USA 7 Institute for Cell Biology (IFZ), University Hospital Essen, 45122 Essen, Germany; [email protected] * Correspondence: [email protected] Citation: Körholz, K.; Ridinger, J.; Abstract: Depending on context and tumor stage, deregulation of autophagy can either suppress Krunic, D.; Najafi, S.; Gerloff, X.F.; tumorigenesis or promote chemoresistance and tumor survival.
    [Show full text]
  • Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences
    cancers Article Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences Stefanie Lietke 1,2,† , Michael Schmutzer 1,2,† , Christoph Schwartz 1,3, Jonathan Weller 1,2 , Sebastian Siller 1,2 , Maximilian Aumiller 4,5 , Christian Heckl 4,5 , Robert Forbrig 6, Maximilian Niyazi 2,7, Rupert Egensperger 8, Herbert Stepp 4,5 , Ronald Sroka 4,5 , Jörg-Christian Tonn 1,2, Adrian Rühm 4,5,‡ and Niklas Thon 1,2,*,‡ 1 Department of Neurosurgery, University Hospital, LMU Munich, 81377 Munich, Germany 2 German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany 3 Department of Neurosurgery, University Hospital Salzburg, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria 4 Laser-Forschungslabor, LIFE Center, University Hospital, LMU Munich, 81377 Munich, Germany 5 Department of Urology, University Hospital, LMU Munich, 81377 Munich, Germany 6 Institute for Clinical Neuroradiology, University Hospital, LMU Munich, 81377 Munich, Germany 7 Department of Radiation Oncology, University Hospital, LMU Munich, 81377 Munich, Germany 8 Center for Neuropathology and Prion Research, University Hospital, LMU Munich, 81377 Munich, Germany * Correspondence: [email protected]; Tel.: +49-89-4400-0 † Both authors contributed equally. ‡ This study is guided by AR and NT equally thus both serve as shared last authors. Citation: Lietke, S.; Schmutzer, M.; Schwartz, C.; Weller, J.; Siller, S.; Simple Summary: Malignant glioma has a poor prognosis, especially in recurrent situations. Intersti- Aumiller, M.; Heckl, C.; Forbrig, R.; tial photodynamic therapy (iPDT) uses light delivered by implanted light-diffusing fibers to activate Niyazi, M.; Egensperger, R.; et al. a photosensitizing agent to induce tumor cell death. This study examined iPDT for the treatment Interstitial Photodynamic Therapy of malignant glioma recurrences.
    [Show full text]
  • Targeted Therapy–Based Combination Treatment in Rhabdomyosarcoma Anke E.M
    Review Molecular Cancer Therapeutics Targeted Therapy–based Combination Treatment in Rhabdomyosarcoma Anke E.M. van Erp1, Yvonne M.H. Versleijen-Jonkers1, Winette T.A. van der Graaf1,2, and Emmy D.G. Fleuren3 Abstract Targeted therapies have revolutionized cancer treatment; in this regard, as this affects multiple hallmarks of cancer at however, progress lags behind in alveolar (ARMS) and embry- once. To determine the most promising and clinically relevant onal rhabdomyosarcoma (ERMS), a soft-tissue sarcoma mainly targeted therapy–based combination treatments for ARMS and occurring at pediatric and young adult age. Insulin-like growth ERMS, we provide an extensive overview of preclinical and factor 1 receptor (IGF1R)-directed targeted therapy is one of the (early) clinical data concerning a variety of targeted therapy– few single-agent treatments with clinical activity in these dis- based combination treatments. We concentrated on the most eases. However, clinical effects only occur in a small subset of common classes of targeted therapies investigated in rhabdo- patients and are often of short duration due to treatment myosarcoma to date, including those directed against receptor resistance. Rational selection of combination treatments of tyrosine kinases and associated downstream signaling path- either multiple targeted therapies or targeted therapies with ways, the Hedgehog signaling pathway, apoptosis pathway, chemotherapy could hypothetically circumvent treatment resis- DNA damage response, cell-cycle regulators, oncogenic fusion tance mechanisms and enhance clinical efficacy. Simultaneous proteins, and epigenetic modifiers. Mol Cancer Ther; 17(7); 1365–80. targeting of distinct mechanisms might be of particular interest Ó2018 AACR. Introduction treatment including surgery, chemotherapy, and radiotherapy has increased the 5-year overall survival (OS) to approximately Rhabdomyosarcoma is the most common type of soft-tissue 70%–90% for intermediate- and low-risk rhabdomyosarcoma, sarcoma (STS) observed in young patients with the most respectively.
    [Show full text]
  • Temozolomide Use in IDH-Mutant Gliomas
    cells Review From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas Xueyuan Sun and Sevin Turcan * Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany; [email protected] * Correspondence: [email protected] Abstract: In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating IDH-mutant glioma. Lastly, we summarize the emerging therapeutic targets that can potentially be used in combination with TMZ. Keywords: IDH-mutant glioma; TMZ; combination therapy 1. Introduction Gliomas are the most common primary malignant tumors in the central nervous system. Grade 2 and 3 gliomas are referred to as lower grade gliomas (LGG) and harbor mutations in the isocitrate dehydrogenase (IDH) gene [1]. IDH-mutant gliomas have a slower growth rate and longer survival than IDH wild type (IDH-wt) tumors [1,2]. IDH- Citation: Sun, X.; Turcan, S. From mutant gliomas are classified into two subgroups based on the presence (astrocytoma) or Laboratory Studies to Clinical Trials: absence (oligodendroglioma) of chromosome arms 1p/19q [3] and histological criteria [4]. Temozolomide Use in IDH-Mutant Recently, the European Association of Neuro-Oncology (EANO) stratified IDH-mutant Gliomas. Cells 2021, 10, 1225. gliomas into three WHO grades: oligodendroglioma, WHO grade 2 or 3; astrocytoma, https://doi.org/10.3390/cells10051225 WHO grade 2 or 3; astrocytoma, WHO grade 4 [5].
    [Show full text]
  • Intravesical Treatment with Vorinostat Can Prevent Tumor Progression in MNU Induced Bladder Cancer
    Journal of Cancer Therapy, 2013, 4, 1-6 http://dx.doi.org/10.4236/jct.2013.46A3001 Published Online July 2013 (http://www.scirp.org/journal/jct) Intravesical Treatment with Vorinostat Can Prevent Tumor Progression in MNU Induced Bladder Cancer Degui Wang1, Siwei Ouyang1, Yingxia Tian1,2*, Yan Yang2, Bo Li2, Xiangwen Liu1,Yanfeng Song1* 1Department of Anatomy, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China; 2Gansu Medical Research Insti- tute, Lanzhou, China. Email: *[email protected], *[email protected] Received February 24th, 2013; revised March 29th, 2013; accepted April 6th, 2013 Copyright © 2013 Degui Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Histone deacetylase inhibitors (HDACI) are promising class of drugs acting as antiproliferative agents by promoting differentiation as well as inducing apoptosis. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is the first among this new class of anticancer drugs to be approved by FDA for the treatment of cancer but only for cutaneous T cell lymphoma (CTCL). The objective of this study is to investigate the inhibitory effect of SAHA on the viability of human bladder cancer cells and its synergetic effect with chemotherapy agents in vitro and in vivo. Methods: The cell viability of human bladder cancer cell lines after treated with SAHA or SAHA combining mitomycin c (MMC), Cis- platin (DDP) and Adriamycin (ADM) were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro- mide (MTT) assay.
    [Show full text]
  • Cip1 and P27kip1 in Hdaci-Mediated Tumor Cell Death and Cell Cycle Arrest in the Em-Myc Model of B-Cell Lymphoma
    Oncogene (2014) 33, 5415–5423 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc ORIGINAL ARTICLE The role of p21waf1/cip1 and p27Kip1 in HDACi-mediated tumor cell death and cell cycle arrest in the Em-myc model of B-cell lymphoma A Newbold1, JM Salmon1, BP Martin1, K Stanley1 and RW Johnstone1,2 Following the establishment of histone deacetylases (HDACs) as promising therapeutic targets for the reversal of aberrant epigenetic states associated with cancer, the development of HDAC inhibitors (HDACi) and their underlying mechanisms of action has been a significant area of scientific interest. HDACi induce diverse biological responses including the inhibition of cell proliferation by blocking progression through the G1 or G2/M phases of the cell cycle. As a putative tumor-suppressor protein, p21waf1/cip1 influences cell proliferation by inhibiting the activity of cyclin–cyclin-dependent kinase (CDK) complexes at the G1/S and G2/M cell cycle checkpoints. HDACi transcriptionally activate CDKN1A, and it has been proposed that induction of p21waf1/cip1 can determine if a cell undergoes apoptosis or cell cycle arrest following HDACi treatment. In the Em-myc transgenic mouse model of B-cell lymphoma, knockout of cdkn1a had no effect on disease latency, indicating that p21waf1/cip1 did not function as a tumor suppressor in this system. Although HDACi robustly induced expression of p21waf1/cip1 in wild-type Em-myc lymphomas, deletion of cdkn1a did not sensitize the lymphoma cells to HDACi-induced apoptosis and HDACi-induced cell cycle arrest still occurred. However, knockdown of cdkn1b in cdkn1a knockout lymphomas resulted in defective vorinostat-mediated arrest at G1/S indicating an essential role of p27Kip1 in mediating this biological response to vorinostat.
    [Show full text]
  • The Effects of Taxanes, Vorinostat and Doxorubicin on Growth And
    www.impactjournals.com/oncotarget/ Oncotarget, 2018, Vol. 9, (No. 10), pp: 9073-9087 Research Paper The effects of taxanes, vorinostat and doxorubicin on growth and proliferation of Echinococcus multilocularis metacestodes assessed with magnetic resonance imaging and simultaneous positron emission tomography Xiangsheng Huang1,*, Stefan Wiehr2,*, Anna-Maria Wild2, Patrick Voßberg1, Wolfgang Hoffmann1, Beate Grüner3, Carsten Köhler1 and Peter T. Soboslay1 1Institute for Tropical Medicine, Eberhard Karls University, Tübingen, Germany 2Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany 3Section of Clinical Immunology and Infectiology, University Clinics Ulm, Ulm, Germany *These authors contributed equally to this work Correspondence to: Peter T. Soboslay, email: [email protected] Keywords: echinococcus multilocularis, metacestode; taxanes, paclitaxel, docetaxel, histone deacetylase inhibitor, vorinostat, doxorubicin; drug exposure; positron emission tomography; magnetic resonance imaging Received: August 09, 2017 Accepted: January 02, 2018 Published: January 10, 2018 Copyright: Huang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Cytostatic drugs used in cancer therapy were evaluated for their capacity to inhibit Echinococcus multilocularis metacestode growth and proliferation. Metacestode tissues were exposed in vitro to docetaxel, doxorubicin, navelbine, paclitaxel, and vorinostat for 1 week, then incubated in drug-free culture, and thereafter metacestodes were injected into the peritoneum of Meriones unguiculatus. Magnetic resonance imaging (MRI) and simultaneous positron emission tomography (PET) were applied to monitor in vivo growth of drug-exposed E.
    [Show full text]
  • Solubilization of Vorinostat by Cyclodextrins
    Journal of Clinical Pharmacy and Therapeutics (2009) 34, 1–6 doi:10.1111/j.1365-2710.2009.01095.x ORIGINAL ARTICLE Solubilization of vorinostat by cyclodextrins Y. Y. Cai* BSc,C.W.Yap*PhD,Z.Wang*BEng,P.C.Ho*PhD,S.Y.Chan*PhD, K. Y. Ng* PhD,Z.G.Ge PhD MBBS and H. S. Lin* PhD *Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore and Department of Biomedical Engineering, College of Engineering, Peking University, Beijing, China using RM-b-CD as an oral absorption enhancer. SUMMARY Molecular simulation appeared to be a useful tool Background: Vorinostat (suberoylanilide hydro- for the selection of appropriate CD as excipient for xamic acid) is the first histone deacetylase inhib- drug delivery. itor approved by US FDA for use in oncology. However, as a hydrophobic acid, its limited Keywords: cyclodextrin, inclusion complex, mole- aqueous solubility poses a problem for parenteral cular simulation, phase solubility, vorinostat delivery. Such limited solubility may also affect its oral bioavailability. INTRODUCTION Objective: The aim of this study was to evaluate whether cyclodextrins (CDs), common excipients Vorinostat, also known as suberoylanilide used in pharmaceutical industry, could increase hydroxamic acid or N-hydroxy-N¢-phenyloctane- the aqueous solubility of vorinostat. diamide (Fig. 1), is a histone deacetylase inhibitor Methods: The actual aqueous solubility of originally developed by Marks and Breslow for its vorinostat was investigated by phase-solubility anti-neoplastic effects (1). Vorinostat effectively method. Molecular simulation was employed to induces cell cycle arrest, cell differentiation and ⁄ or predict the interaction energy and preferred apoptotic cell death in various transformed cells at orientation of vorinostat in CD cavities.
    [Show full text]
  • ZOLINZA Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Patients with mild and moderate hepatic impairment should be These highlights do not include all the information needed to use treated with caution. (5.4) ZOLINZA safely and effectively. See full prescribing information • Hyperglycemia has been observed. Adjustment of diet and/or for ZOLINZA. therapy for increased glucose may be necessary. (5.5, 5.6) • Monitor electrolytes at baseline and periodically during treatment. ZOLINZA® (vorinostat) Capsules (5.6) Initial U.S. Approval: 2006 • Monitor blood cell counts and chemistry tests, including electrolytes, ---------------------------RECENT MAJOR CHANGES --------------------------­ glucose and serum creatinine, every 2 weeks during the first 2 Dosage and Administration months of therapy and monthly thereafter. (5.6) • Dosing in Special Populations (2.3) XX/20XX Severe thrombocytopenia and gastrointestinal bleeding have been Contraindications (4) XX/20XX reported with concomitant use of ZOLINZA and other HDAC Warnings and Precautions inhibitors (e.g., valproic acid). Monitor platelet count. (5.7, 7.2) • Hepatic (5.4) XX/20XX Fetal harm can occur when administered to a pregnant woman. Women should be apprised of the potential harm to the fetus. (5.8) ----------------------------INDICATIONS AND USAGE---------------------------­ ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for: ------------------------------ ADVERSE REACTIONS -----------------------------­ • • Treatment of cutaneous manifestations in patients with cutaneous T- The most common
    [Show full text]